argenx SE

• Positive Phase 3 ALKIVIA trial results for VYVGART Hytrulo boosted shares. • Analysts reaffirmed positive ratings despite price target adjustments for secondary indications. • Argenx reports annual revenue of $4.15B and net profit of $1.29B.

• Argenx discontinued its Phase 3 UNITY study for Sjogren's disease due to futility. • The trial termination overshadowed positive mid-stage Phase 2 results for FB102. • Core commercial products generate robust cash flows despite the late-stage setback.

• Argenx announced positive Phase 3 ALKIVIA study results for VYVGART Hytrulo in myositis. • The company reported $4.15 billion in annual revenue and $1.29 billion in net profit. • Analysts issued Buy ratings with an average price target of $1083.77.